Predicting patients at risk for pain associated with electrochemotherapy
Pietro Quaglino(Department of Medical Sciences), Julie Gehl(University of Copenhagen), Francesca de Terlizzi(Interventi Geo Ambientali (Italy)), Valerie Letulé(Ludwig-Maximilians-Universität München), Rikke Albret(University of Copenhagen), Giulia Bertino(University College Cork), Christian Kunte(München Klinik), Marco Benazzo(University of Pavia), Federica Marenco(University Dermatology), Carol Cuthbert(St George's Hospital), Roberta Rotunno(Sapienza University of Rome), Louise Wichmann Matthiessen(University of Copenhagen), Alison Humphreys(James Cook University Hospital), P. Curatolo(Sapienza University of Rome), Tobian Muir(James Cook University Hospital), Joy Odili(St George’s University Hospitals NHS Foundation Trust)
Cited by 62
Related Papers
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
|JAMA Dermatology|2015|452
European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017
|European Journal of Cancer|2017|449